AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04199871 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: dichoptic 3D movies
Description: dichoptic movies presented on a Nintendo 3DS
Study NCT04199871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dichoptic 3D movies
Description: dichoptic movies presented on a Nintendo 3DS
Study NCT05829343 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Left colectomy
Description: Patients are treated with a laparoscopic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
Study NCT05829343 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic left colectomy
Description: Patients are treated with a robotic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
Study NCT05626634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP352, bexicaserin
Description: LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube
Study NCT04655755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT05486572 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Abbreviated Magnetic Resonance Imaging with serum AFP
Description: Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8
Study NCT05486572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Ultrasound Screening with serum AFP
Description: abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
Study NCT04964986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
Study NCT06146751 — intervention group
Intervention type: DRUG
Intervention: Superparamagnetic Iron Oxide Nanoparticles
Description: Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
Study NCT05197400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: preoperative airway ultrasonography
Description: Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness
Study NCT05197400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: postoperative airway ultrasonography
Description: Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness
Study NCT06473779 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: IMP. Subcutaneous injection. Unit dose strengths 210 mg.
Study NCT06473779 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation
Study NCT06473779 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albuterol/budesonide (AIRSUPRA®)
Description: AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.
Study NCT06473779 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules
Study NCT06473779 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation
Study NCT05480098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Topical
Description: Topical brimonidine intraoperatively for hemostasis
Study NCT06584292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: Caudal Block (CB) Procedure: The sacral hiatus was identified using an out-of-plane transverse ultrasound view at the level of the sacral cornua. The probe was then rotated longitudinally to visualize the sacrococcygeal ligament and sacral bone. A block needle was inserted through the sacrococcygeal membrane into the sacral canal using the in-plane technique, and 0.125% bupivacaine was administered at a dose of 1 mL/kg, with a maximum limit of 20 mL per side.
Study NCT06584292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrolaminar block
Description: Retrolaminar Block (RL) Procedure: The RL block was performed with the patient in a lateral decubitus position. The ultrasound probe was positioned at the L4 vertebral level in a paramedian sagittal plane. The probe was moved medially until the vertebral laminae were visualized. The needle was inserted using the in-plane technique, advancing from the cephalad to caudal direction until it contacted the L4 lamina. A dose of 0.1 mL/kg of 0.25% bupivacaine was then injected into the retrolaminar space.
Study NCT05302063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Description: Boston Scientific Spinal Cord Stimulation Systems with multiple modalities
Study NCT06349889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Drug: Adebrelimab Adebrelimab 1200mg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.~Other Names:~PD-L1 antibody~Drug: Gemcitabine Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Other Names:~GEM~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation~Other Names:~DDP~Radiation: Intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.~Other Names:~IMRT
Study NCT06492616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Administered as oral tablets
Study NCT05818553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-562
Description: Once daily oral or G-tube treatment.
Study NCT05848947 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 99mTc-Macro Albumin Aggregate
Description: Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.
Study NCT04679935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal injection
Study NCT06541067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Per Os, on Day 0 of allo-CSH if the patient's condition permits, or after the last dose of immunosuppressor (post-transplant cyclophosphamide) (Day+5 or Day+6 depending on protocols).~On the first day of treatment: 300 mg in the morning (= 3 x 100 mg tablets) and 300 mg in the evening (= 3 x 100 mg tablets), then from day 2 of treatment: 300 mg per day (= 3 x 100 mg tablets) in a single dose
Study NCT06451614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpaceIT Hydrogel System
Description: SpaceIT Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceIT Hydrogel System to reduce the radiation dose delivered to the anterior rectum. The SpaceIT Hydrogel System is composed of a radiopaque, biodegradable material designed to maintain space for approximately 12 weeks and be absorbed in about 6 months, sufficient time to support the intended use.~SpaceIT has an iodinated PEG powder making it radiopaque.
Study NCT06451614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Boston Scientific Spacer
Description: Boston Scientific's commercially available SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System to reduce the radiation dose delivered to the anterior rectum. SpaceOAR and SpaceOAR Vue are both perirectal spacers. SpaceOAR Vue specifically has an iodinated PEG powder making it radiopaque. SpaceOAR does not contain iodinated PEG powder and is not radiopaque. The SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System maintains space during prostate radiotherapy treatment and is completely absorbed by the patient's body over time.
Study NCT06374667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Y-3 ICO injection
Description: Patients included will be given skull outer plate drilling surgery and Y-3 ICO injection under local anesthesia and sedation. The injection will be given for 3 consecutive days.
Study NCT06374667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Y-3 intravenous injection
Description: Patients included will be given Y-3 intravenous injection for 7 consecutive days.
Study NCT06374667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: standard treatment and management according to related guidelines during the entire treatment period
Study NCT06374667 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: standard treatment and management according to related guidelines during the entire treatment period
Study NCT06185192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viome's Precision Nutrition Program (VPNP)
Description: Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
Study NCT06505239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FSD-F2R6-A-CP
Description: FSD-F2R6-A-CP is a unique dietary supplement with natural ingredients, vitamins and minerals that potentially enhances cognition, replenishes cofactors needed for alcohol metabolism and may accelerate alcohol metabolism in the body.
Study NCT06505239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink designed to match FSD-F2R6-A-CP in color and taste.
Study NCT05929859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Motor Chaining
Description: Sessions begin with Pre-practice to elicit target sounds, with verbal cueing and shaping strategies. During Structured Practice, items are practice in blocks of 6 consecutive trials (with systematic increases in difficulty), and our web-based software will manipulate the principles of motor learning, including the stimulus prompt, the participant's production, analysis of the clinician's rating, feedback prompts for the clinician, and the variability present in the practice trial. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order.
Study NCT05685173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Odronextamab will be administered by IV infusion
Study NCT05685173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5837
Description: REGN5837 will be administered by IV infusion
Study NCT05044312 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sleeping Disturbances
Description: most common complaints of patients after surgery and may affect the ability to carry out daily activities, quality of life, and post-surgery recovery.
Study NCT05273788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2400 ThorS-MagNT Stimulations at 1Hz
Description: The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 1 Hz ThorS-MagNT, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
Study NCT05273788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2400 ThorS-MagNT Stimulations at 10Hz
Description: The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 10Hz ThorS-MagNT involves delivering one train of 100 pulses per minute with 50-second rest intervals over twelve minutes on both right and left sides (total 1200 pulses/side).
Study NCT05273788 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulations
Description: The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. Sham stimulations, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
Study NCT06515912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Diet
Description: A ketogenic diet with 5% carbohydrate, 18% protein, and 77% fat by percent kcal.
Study NCT06515912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: A ketogenic diet with 5% carbohydrate, 18% protein, and 77% fat by percent kcal.
Study NCT06459024 — intervention group
Intervention type: OTHER
Intervention: Registration into the STREAM platform
Description: All patients fulfilling eligibility criteria will be registered into the STREAM platform. Baseline and follow up information will be recorded for each patient enrolled. Each patient will be followed up according to normal clinical practice up to 4 years.
Study NCT06256640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement Device
Description: Intra oral appliances and more specifically Mandibular Advance Devices (MAD) are one of the established alternatives to treat OSA. Oral appliances and MAD are often used interchangeably but we prefer to call them MAD as it is more descriptive of its mechanism of action. MAD are placed in the mouth to temporarily advance and stabilize the lower jaw forward in order to keep the airway open during sleep.
Study NCT06224673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: Given IV
Study NCT06224673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo CT or Positron Emission Tomography(PET)/CT
Study NCT06224673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06224673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Ophthalmologic drops given topically to participants for an eye toxicity substudy
Study NCT05184816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO)
Description: The accelerated single-patient dose escalation will apply to dosing cohorts 1 through 4 (10mg, 30mg, 60mg, 100mg) and will convert to a 3+3 dose escalation for cohorts 5 through 9 (150mg, 210mg, 280mg, 372mg, 495mg).
Study NCT06385353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantification of deep vein thrombosis burden and assessment of post-thrombotic syndrome
Description: Post-thrombotic syndrome will be assessed by the Villalta score until 6 months of follow-up.~Data collected from colour doppler ultrasound will be used to calculate the Venous Volumetric Index to quantify deep vein thrombosis burden until 6 months of follow-up.
Study NCT04981600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Patients in the RF group will be first examined under anesthesia at the beginning of the procedure in lithotomy position. Approximately 3-6 ml of 20 mg/ml Lidocaine (Jetokaine, Adeka İlaç Sanayi, Samsun) solution will be injected between the cushion and the internal anal sphincter to minimize heat conduction to the surrounding tissues during the procedure. The HPR45i probe (F Care Systems, Antwerpen, Belgium) connected to the Rafaelo ® EVRF machine (F Care Systems, Antwerpen, Belgium) will be placed inside the cushion and 25 watts of RF energy will be transmitted. Care will be taken by not exceeding the dentate line caudally. The recommended Joule value for each operation is 1200-3000 J. Then cold is applied on the cushion, reducing the temperature of the tissue and preventing damage to the surrounding tissues. The same procedure will be performed for other pathologic cushions as well.
Study NCT04981600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: The same preoperative preparations will be done for the laser group as well. The NeoV 1470 (neoLaser, Israel) device will be used in this group. Following routine placement of the patient in lithotomy position and determining the cushion to be treated, a 12 W laser beam with a wavelength of 1470nm will be inserted into the cushion above the dentate line and advanced to the apex and approximately 3 laser shots are delivered throughout the course caudally, the number of which can be altered according to the size targeted cushion. Finally the procedure will be completed after gentle cold application.~An enema will be given to the patients in both study groups in the morning of the operation and patients will be discharged with analgesics on the same day.
Study NCT05789082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Participants will receive one of two doses of divarasib orally (PO), QD on days 1-21 of each 21-day cycle.
Study NCT05789082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.
Study NCT05789082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive IV carboplatin Q3W for four 21-day cycles.
Study NCT05789082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive IV cisplatin Q3W for four 21-day cycles.
Study NCT05789082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive IV pemetrexed Q3W.
Study NCT05948995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abduction external rotation brace
Description: Abduction external rotation brace Arm position : Abduction , External rotation
Study NCT04954885 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo stool sample
Study NCT04954885 — intervention group
Intervention type: OTHER
Intervention: Physical Performance Testing
Description: Undergo short physical performance battery
Study NCT04954885 — intervention group
Intervention type: OTHER
Intervention: Physical Performance Testing
Description: Perform 6-minute walk test
Study NCT04954885 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT05646836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
Study NCT05646836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb24306
Description: XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
Study NCT05646836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
Study NCT05039866 — intervention group
Intervention type: BIOLOGICAL
Intervention: ST-920
Description: No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
Study NCT05920889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: 0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. patient will receive a total of 2 injections.
Study NCT05955846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery
Description: Subjects will undergo surgery to remove cataract (natural cloudy lens) via phacoemulsification implant the IOL Both eyes will be treated one month apart. Subjects will be followed up during 12 months
Study NCT05955846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implantation of device IOL FG-80030.1
Description: implant the IOL in both eyes. Both eyes will be treated one month apart. Subjects will be followed up during 12 months
Study NCT05284409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: 36 patients will receive 0.5 mg/kg Pethidine IVI